Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
Phuong Khanh Morrow, Board Member of Reagan-Udall Foundation for the FDA, Senior Vice President and Head of Oncology Therapeutic Area Unit (OTAU) at Takeda, Board Member of Lantheus, shared a post on LinkedIn:
“Patients living with PV often have limited treatment options to help them manage this chronic and difficult blood cancer. This shines a light on the pressing need for additional treatment options.
As an oncologist, an FDA approval is never just a milestone – it’s a moment where science meets real possibility for patients!
This approval represents an important step forward for the PV community.
Progress like this underscores why continued scientific innovation matters and why we remain focused on advancing options that can make a meaningful difference for patients!”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB
-
Sep 3, 2026, 17:24N. Mariana S. Vasquez: JAK2 Mutations The High-Yield Map of Myeloproliferative Neoplasms
-
Sep 3, 2026, 17:08Khusi Dhara: Why Women Need to Pay Attention to Iron